Pontificia Universidad Catolica de Chile

uc.cl

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

212

Active

40

Phase 3

9

Total enrollment

126,073

Pipeline matrix

Showing 10 of 10 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Lidocaine3
Colchicine1
Surgical implantation with standard (DRM) or photosynthetic dermal regeneration matrices (PDRM) in same patient.1
Propofol5
Sedative1
Hemodynamic monitor, BIS, TOF, ANI, anesthesia machine and infusion pumps1
Tuberculosis window prophylaxis with weekly rifapentine and isoniazid for 12 weeks1
Standard of care tuberculosis prophylaxis with weekly rifapentine and isoniazid for 12 weeks1
Infliximab1
administration of dexamethasone intravenously1

Next readouts

  • 2026-01
  • 2026-03-30
  • 2026-07-01
  • 2026-07-01
  • 2026-10-27
  • 2026-12-01
  • 2026-12-01
  • 2028-05
  • 2028-05

Top conditions

  • Anesthesia13
  • Pain7
  • Covid197
  • Obesity6
  • Septic Shock6
  • Breast Cancer6
  • Critical Illness5
  • Surgery4

Frequently asked questions about Pontificia Universidad Catolica de Chile

How many clinical trials does Pontificia Universidad Catolica de Chile have on ClinicalTrials.gov?
Pontificia Universidad Catolica de Chile is listed as the lead sponsor on 212 clinical trials in ClinicalTrials.gov, 40 of which are currently active (recruiting, enrolling, or ongoing).
How many of Pontificia Universidad Catolica de Chile's trials are in Phase 3?
9 of Pontificia Universidad Catolica de Chile's trials are in Phase 3, spread across 10 active drug programs.
What therapeutic areas does Pontificia Universidad Catolica de Chile focus on?
Pontificia Universidad Catolica de Chile's most-studied conditions on ClinicalTrials.gov are Anesthesia, Pain, Covid19, Obesity, Septic Shock.
When are Pontificia Universidad Catolica de Chile's next clinical trial readouts?
Pontificia Universidad Catolica de Chile has 9 upcoming primary-completion readouts tracked here; the soonest is “PROactive and Early Infliximab Monitoring and OPTimization in Inflammatory Bowel Disease”, expected around 2026-01.